Important Safety Information
Indications for Use (IFU): The MRIdian Linac system, with magnetic resonance imaging capabilities, is intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated. The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging.
Important Safety Information (ISI): Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration.
Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.
Disclaimer: The opinions and clinical experiences presented herein are specific to the featured physicians and the featured patients and are for information purposes only. Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations. Results of treatment presented in the videos and information on this webpage are not indicative of typical or future results.
Discuss treatment options with your doctor, including the risks and benefits of the entire course of treatment specific to your individual needs. MRIdian Linac systems are only available at appropriately equipped facilities with specially trained physicians.
“ViewRay’s MRIdian is our first choice treatment for partial breast irradiation because we can actually see the treatment live and reduce certain errors that are known to happen with CT-based treatment. We’re no longer limited to the ‘peek and shoot’ mentality of other treatments.”
Phillip Beron, MD
UCLA
UCLA Clinical Experience with MRI-guided Adaptive Radiotherapy: Stereotactic Body Radiotherapy (SBRT)/Stereotactic Ablative Radiotherapy (SABR) for Abdominal Tumors and Accelerated Partial Breast Radiotherapy (APBR) for Breast CancerRadiosurgery Society
Webinar Held April 21, 2016
Noteworthy Clinical Findings
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO recently completed a prospective phase I/II trial of 50 patients. It showed that single-fraction HG-PBI was well tolerated and resulted in few adverse events.
Study Specifics
Patients received postoperative single-fraction 20 Gy dose to the cavity surface while simultaneously prescribing 5 Gy to a PTV defined as the surgical bed plus a 1 cm margin
Key Findings
- No grade 3-5 toxicities observed
- 100% excellent to good cosmesis reported by both patients and treating physicians
- Patient-reported quality of life did not decrease after treatment
- Excellent early local, regional, and distant control rates
This study, Kennedy et al. (2020), was published in the February issue of the International Journal of Radiation Oncology * Biology * Physics.
Visible Benefits with MRIdian
MRIdian Bibliography
Scientific Presentations Related To Breast Cancer
Extreme Hypofractionated MRI-Guided Partial Breast Treatments, Clinical Outcomes on MRIdian
Imran Zoberi, MD
Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine
ASTRO 2019
Dr. Zoberi has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
Physician Experience with MR Image-Guided RT for Breast Cancer
Imran Zoberi, MD
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
ASTRO 2018
Dr. Zoberi has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
MR-IGRT for Accelerated Partial Breast Irradiation (APBI)
Maria Thomas, MD
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine – St. Louis, MO
ASTRO 2017
Dr. Thomas has been compensated by ViewRay for her services in preparing and presenting this material for ViewRay’s further use and distribution.
MR-Guided Breast Radiotherapy
Maria Thomas, MD, PhD
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine – St. Louis, MO
Advanced Applications of MR-Guided Radiotherapy Symposium (Amsterdam, 2018)
Dr. Thomas has been compensated by ViewRay for her services in preparing and presenting this material for ViewRay’s further use and distribution.
Videos Related To Breast Cancer
ViewRay MRIdian for Prostate, Breast, and Pancreatic Cancer Treatment
October 22, 2019